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It is unknown whether clinical characteristics can successfully predict which multiple myeloma (MM) pa-
tients would be poor mobilizers with growth factor (GF) alone so they can be assigned to mobilization with
chemotherapy þ GF or GF þ plerixafor. MM patients (N ¼ 477) who underwent autologous mobilization with
GF were retrospectively reviewed and assigned into training and validation cohorts. In multiple regression
analysis, age, platelet count at time of mobilization, type of GF utilized, and extent of exposure to lenalido-
mide independently correlated with peripheral blood (PB)-CD34þ and were integrated in a predicting score
(PS) for poor mobilizers, deﬁned as PB-CD34þ < 20/mm3 4 days after initiation of GF. There was no corre-
lation between institution, gender, time between diagnosis, and mobilization or plasma cells in the bone
marrow at time of mobilization and PBCD34þ. The PS cut-off found in the training cohort to have 90%
sensitivity for prediction of poor mobilizers performed with 89.7% sensitivity but only 34.8% speciﬁcity in the
validation cohort. Conversely, the PS cut-off developed to have 90% speciﬁcity performed with 86.9% speci-
ﬁcity but only 37% sensitivity. We conclude that clinical characteristics identiﬁable before initiation of
mobilization should not be used to stratify MM patients for different mobilization strategies.
 2014 American Society for Blood and Marrow Transplantation.INTRODUCTION reduce the risk of mobilization failure and increase CD34þ
Autologous hematopoietic progenitor cell transplantation
after high-dose chemotherapy is a common and effective
treatment for patients with multiple myeloma (MM) [1-4].
This procedure requires the prior procurement and cryo-
preservation of hematopoietic progenitor cells to ensure safe
engraftment [5].
The administration of hematopoietic growth factors
(GFs), particularly granulocyte-colony stimulating factor (G-
CSF) or granulocyte macrophage-colony stimulating factor, is
the simplest method to mobilize hematopoietic progenitor
cells (HPCs). GFs stimulate neutrophil production, matura-
tion, and protease release, leading to disruption of the
binding of CD34þ progenitor cells from the bone marrow
stroma and its consequent migration to the peripheral blood
[6]. The most important interaction disrupted is the 1 be-
tween the receptor CXCR4 (present in CD34þ cells) and its
ligand, CXCL12 or stromal-derived growth factore1 [7].
Two other strategies are known to increase the CD34þ
yield and reduce mobilization failure when compared with
GF-alone mobilization. The administration of chemo-
therapy, particularly high-dose cyclophosphamide followed
by daily GF, improves CD34þ yield but is associated with
higher risk of complications, particularly fever and neu-
tropenia [8,9]. More recently, the combination of G-CSF and
plerixafor, an inhibitor of CXCR4 that prevents its binding
to stromal-derived growth factore1, has been shown toedgments on page 227.
equests: Luciano J. Costa, MD, PhD, 96
SC 635, Charleston, SC 29425-6350.
du (L.J. Costa).
2014 American Society for Blood and Marrow
13.11.003yield [10]. Plerixafor has a favorable side effect proﬁle but a
high cost, making it not cost effective on a substantial
proportion of patients who would mobilize properly with
GF alone.
Considering the caveats of each mobilization strategy, it
would be of great value to risk stratify patients in regards to
their risk of “poor mobilization” with GF alone so they can
proceed with chemotherapy þ GF or GF þ plerixafor mobi-
lization. In the present study, we utilized a large cohort of
MM patients undergoing ﬁrst mobilization with GF to
develop a predictive model for poor mobilization and tested
the operational characteristics of this model in an indepen-
dent but similar cohort.
MATERIALS AND METHODS
This is a retrospective study utilizing data on consecutive patients
with MM who underwent ﬁrst autologous HPC mobilization at the Mayo
Clinic, Rochester, Minnesota (Mayo) or at the Medical University of South
Carolina, Charleston, South Carolina (MUSC) utilizing primarily GF, be-
tween 2000 and early 2013. Information of interest included gender, age,
duration of prior therapy with speciﬁc myeloma drugs, percentage of
plasma cells in the bone marrow before mobilization (within a month and
with no subsequent antimyeloma therapy), platelet count before mobili-
zation, time between diagnosis and mobilization, and number of CD34þ
cells in the peripheral blood (PB-CD34þ) on the fourth day after initiation
of administration of GF. The majority of patients were managed elsewhere
before being referred to our institutions for transplantation. Relevant in-
formation on prior use of radiation was not consistently captured and
veriﬁed and, therefore, not available for the majority of patients in our
mobilization databases. The vast majority of patients received ﬁlgrastim as
mobilizing GF at the dose of 10 mg/kg/day, with the exception of 84 pa-
tients from MUSC who received pegﬁlgrastim 12 mg as previously re-
ported [11]. Only patients with complete dataset were included in the
analysis. This study was approved by both Mayo and MUSC institutional
review boards.Transplantation.
Table 1
Characteristics of Multiple Myeloma Patients in the Training and Validation Cohorts
Characteristic Training Cohort Validation Cohort All Patients
n ¼ 239 n ¼ 238 N ¼ 477
Institution
Mayo 173 (72.4%) 173 (72.7%) 346 (72.6%)
MUSC 66 (27.6%) 65 (27.3%) 131 (27.4%)
Age, yr* 59.5 (52.8-65.5) 59.4 (52.5-65.3) 59.4 (52.7-65.4)
Male gender 140 (58.6%) 124 (52.1%) 264 (55.3%)
Patients with prior lenalidomide therapy 63 (26.4%) 71 (29.8%) 134 (28.1%)
Plasma cells in bone marrow, %* 6 (2.5-15) 5 (3-15) 5 (3-15)
Platelet count before mobilization* 222 (183.5-277.5) 223 (181.2-285.7) 223 (182-281)
Interval from diagnosis to mobilization, mo* 5.9 (4.8-8.1) 6.1 (4.8-8.7) 6 (4.8-8.5)
Growth factor
Filgrastim 197 (82.4%) 196 (82.3%) 393 (82.4%)
Pegﬁlgrastim 42 (17.5%) 42 (17.6%) 84 (17.6%)
PB-CD34þ* 17 (7-30) 16 (9-25) 16 (8-28)
PB-CD34þ
<10/mm3 72 (30.1%) 65 (27.3%) 137 (28.7%)
<20/mm3 136 (56.9%) 146 (61.3%) 282 (59.1%)
Data presented are n (%) unless otherwise indicated.
* Median (interquartile range).
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There is no consensus in the literature on which patients should be
considered poor mobilizers. Here we utilized an operational deﬁnition of
poor mobilization as the failure to obtain a PB-CD34þ count in PB after
4 days of initiation of GF of 20 cells/mm3 or higher. We adopted this
deﬁnition because, contrary to CD34þ daily apheresis yield or total CD34þ
collection, PB-CD34þ is not dependent on other factors, such as perfor-
mance and parameters of the apheresis equipment, institutional practices
(such as parameters to stop apheresis) or the use of plerixafor on or after day
4. In fact, many of the patients included in this analysis were treated under
previously published algorithms for use of “just in time” plerixafor from
both institutions [12,13]. Moreover, PB-CD34þ has been closely correlated
with apheresis yield [12,14,15]. In a post hoc analysis of the phase III study
comparing G-CSF with G-CSF þ plerixafor, 46.5% of the patients receiving
G-CSF alone had PB-CD34þ<20/mm3 on day 4. Only 83.3% of these patients
collected  2  106 CD34þ/kg (minimum yield) and only 36.7%
collected  6  106 CD34þ/kg (optimal yield). These ﬁgures were respec-
tively 98.6% and 73.9% among the 53.5% of MM patients with PB-CD34þ 
20/mm3, reinforcing our choice of PB-CD34þ <20/mm3 as our operational
deﬁnition of poor mobilization [16].
Of interest, PB-CD34þ has been adopted inmany institutions as a trigger
for “just in time” use of plerixafor [12]. AtMayo, MM patients collecting cells
for more than 1 transplantation procedure (target of 4  106 CD34þ/kg) will
receive plerixafor if PB-CD34þ < 20/mm3 [13], whereas at MUSC, the target
for those patients is 6  106 CD34þ/kg, and they receive plerixafor if
PBCD34þ  25/mm3 [12].Development and Validation of Predictive Model
To obtain 2 comparable cohorts (training cohort and validation cohort),
patients were randomly allocated in the 2 cohorts after stratiﬁcation ac-
cording to 2 factors known to strongly affect mobilization: age [17] and type
of growth factor (ﬁlgrastim and pegﬁlgrastim) [11]. To account for anyTable 2
Clinical Variables Associated with PB-CD34þ in the Training Cohort
Univariate Linear Reg
Beta 95% CI
Age (per year) .370 .577
Gender (male) .990 2.89
Duration of prior lenalidomide therapy 1.396 2.16
% PC in the bone marrow .112 .257
Platelet count (per 1,000/mm3) .066 .045 to
Interval from diagnosis to mobilization (per month) .050 .158
Growth factor* 11.981 7.029
Institutiony 4.570 10.6
CI indicates conﬁdence interval; PC, plasma cells.
* Pegﬁlgrastim versus ﬁlgrastim.
y Mayo versus MUSC.intrinsic difference between Mayo and MUSC, cases were also stratiﬁed by
institution of origin.
In the training cohort, we investigated the contribution of the inde-
pendent variables (age, gender, duration of prior exposure to speciﬁc
myeloma drugs, percentage of plasma cells in the bone marrow before
mobilization, platelet count before mobilization, time from diagnosis to
mobilization, type of growth factor utilized, and institution of origin) in
inﬂuencing the dependent variable, PB-CD34þ, utilizing multiple regression
analysis to determine the best ﬁt predictive model.
Patients were classiﬁed as poor mobilizers (actual PB-CD34þ < 20/
mm3) or good mobilizers (actual PB-CD34þ  20/mm3). We utilized the
results of the multiple regression analysis to generate a predicting score (PS)
for each patient (with lower PS indicating higher risk of poor mobilization).
We subsequently built receiving operator characteristics (ROC) curves,
determining the sensitivity and speciﬁcity of different cut-offs of the PS to
identify patients destined to be poor mobilizers in the training cohorts. The
cut-offs corresponding to the performance parameters of interest (80%
sensitivity, 90% sensitivity, 80% speciﬁcity, and 90% speciﬁcity) where then
applied to the validation cohort.
Because some institutions will consider adequate a GF mobilization
producing a PB-CD34þ of 10 cells/mm3 or greater, we also performed an
exploratory analysis repeating the steps above but deﬁning as poor mobi-
lizers the patients with PB-CD34þ < 10/mm3.Statistics
Categorical variables are described in terms of percentage, whereas
continuous variables are described in terms of median and interquartile
range. Simple regressionwas utilized to establish correlations between each
of the independent variables and PB-CD34þ. The development of the pre-
dictive equation utilized multiple regression with stepwise forward inclu-
sion of independent variables. Comparison of continuous variables between
groups was performed utilizing Mann-Whitney U test. All statistic analysisression Multiple Regression
P Beta 95% CI P
to .162 <.001 .352 .629 to .074 .013
2 to 4.872 .62
7 to -.625 <.001 1.80 2.96 to .64 .003
to .033 .13
.087 <.001 .066 .034 to .099 <.001
to .059 .37
to 16.932 <.001 9.72 3.06 to 16.38 .004
65 to 1.525 .141
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Windows, Version 19.0. Armonk, NY). In all inference analyses, 2-sided P
values of less than .05 were considered to indicate statistical signiﬁcance.
RESULTS
Patient Characteristics
During the periods of interest covered in this study, 606
patients with MM underwent autologous HPC mobilization
with GF among the 2 institutions. Of those, 477 (78.7%) met
eligibility criteria, were included in the analysis, and
randomly assigned to the training cohort (n ¼ 239) or vali-
dation cohort (n ¼ 238). The age range was 21 to 75 years in
the training cohort and 29 to 74 years in the validation
cohort. Patients from Mayo and MUSC were comparable,
except for MUSC patients being mobilized in more recentFigure 1. Receiver operating characteristic (ROC) displaying the performance of dif
validation cohort (C and D) and both cohorts combined (E and F).years and have greater exposure to lenalidomide. As dis-
played in Table 1, training and validation cohorts were
comparable in all relevant aspects.Predictors of Poor Mobilization
As described in methods, we utilized multiple regression
to determine the factors independently inﬂuencing PB-
CD34þ and to determine the PS based on those factors
(best ﬁt model). We observed that age and duration of prior
exposure to lenalidomide (but not exposure to cyclophos-
phamide, bortezomib or thalidomide) correlated negatively,
although platelet count at time of mobilization and use of
pegﬁlgrastim instead of ﬁlgrastim correlated positively with
PB-CD34þ. There was no correlation between institutionferent cut-offs of the predicting score (PS) in the training cohort (A and B),
L.J. Costa et al. / Biol Blood Marrow Transplant 20 (2014) 222e228 225(Mayo or MUSC), gender, time between diagnosis and
mobilization, percentage of plasma cells in the bone marrow
at time of mobilization, and PBCD34þ (Table 2). From the
multiple regression model, the equation that best predicts
for PB-CD34þ is:
Predictive score (PS) ¼ .066  platelets (103/mm3) þ
9.721  GF (GF ¼ 0 if ﬁlgrastim, 1 if pegﬁlgrastim) 1.801 
duration of lenalidomide exposure (in months) .352  age
þ 28.254.
There were 136 (56.9%) patients in the training cohort
whowere classiﬁed as poor mobilizers with PB-CD34þ< 20/
mm3 and 72 (30.1%) were poor mobilizers under the PB-
CD34þ < 10/mm3 alternative deﬁnition. Figure 1 display the
ROCs for the training cohort. Utilizing the PB-CD34þ < 20/
mm3 deﬁnition of poor mobilizer, a PS of 29.7 was the cut-off
for 90% sensitivity and a PS of 17.4 was the cut-off for 90%
speciﬁcity. For the PB-CD34þ < 10/mm3 deﬁnition of poor
mobilizer, the cut-offs were 27.6 and 15.6 for 90% sensitivity
and 90% speciﬁcity respectively.
Validation
Overall 146 patients (61.6%) in the validation cohort were
poor mobilizers utilizing the PB-CD34þ < 20/mm3 deﬁni-
tion, whereas 65 (27.4%) were poor mobilizers when the PB-
CD34þ < 10/mm3 alternative deﬁnition was used. When PS
distribution is displayed for actual poor mobilizers and good
mobilizers, it becomes evident that there is great overlap
between the 2 categories, despite the distribution being
statistically different (Figure 2).
Table 3 displays the performance of the cut-off PS derived
from the training cohort when applied to the validation
cohort for optimal sensitivity and optimal speciﬁcity. It be-
comes clear that the use of premobilization clinical charac-
teristics is inadequate to predict poor mobilization. The use
of premobilization clinical characteristics to stratify patients
to different mobilization strategies would lead to either
excessive rate of poor mobilization or unnecessary use of
mobilization alternatives (such as plerixafor) or both.
DISCUSSION
Although GF alone is the simplest and least expensive
method to mobilize autologous CD34þ cells, it has unac-
ceptable shortfalls, particularly lower yields, and higher rates
of mobilization failure. Alternatives to GF-alone mobiliza-
tion, namely GFþ plerixafor or chemotherapyþGF, are moreFigure 2. Distribution of the predicting score (PS) in patients from the validation coh
(GM). In (A) the deﬁnition of PM as PB-CD34þ < 20/mm3 is used, whereas in (B) PM is
range.toxic, more expensive, and/or less convenient but will lead to
better collections [8-10,18,19]. The identiﬁcation of patients
who are likely to have suboptimal collection with GF before
beginning of mobilization would allow transplant physicians
to assign them to an alternative strategy while proceeding
with GF-alone mobilization for the remaining patients.
Several factors have been associated with poor mobili-
zation in MM, including age, bone marrow involvement with
the disease [20], prior lenalidomide therapy [21-23], prior
therapy with melphalan [24-26], number of prior lines of
therapy [24], and extensive irradiation to bone marrow sites
[20,25]. However, no predictive system utilizing those risk
factors has been validated and their performance in risk
stratifying patients for difference mobilization strategies has
not been tested.
In the present analysis, utilizing a large cohort of MM
patients from 2 different institutions and treated with
modern therapy, we identiﬁed age, duration of prior lenali-
domide exposure, platelet count before mobilization, and
type of growth factor utilized for mobilization as indepen-
dent predictors of PB-CD34þ. Of interest, interval between
diagnosis and mobilization and percentage of plasma cells in
the bone marrow before mobilization (a surrogate for
response to therapy and disease burden) did not affect
mobilization (Table 2).
At a time when alternative safe mobilization strategies
are available, more important than having an adequate tool
to predict poor mobilization with GF is to understand its
operational characteristics and the implications of its use for
risk stratiﬁcation. Some institutions have adopted mobiliza-
tion algorithms for the use of plerixafor based on risk strat-
iﬁcation [27]. However, the accuracy of these predicting
systems is unknown. The stratiﬁcation of patients for
different mobilization strategies based on an inaccurate
prediction system may lead to excessive cost (too many
“false-positives,” patients identiﬁed as poor mobilizers but
who would actually mobilize well) or excessive mobilization
failure (too many “false negatives,” identiﬁcation of patients
as good mobilizers, who actually mobilize poorly).
Our ﬁndings from a large and contemporary database
utilizing proper methodology with independent training and
validation cohort indicates that even a robust predictive
model has poor performance. This indicates that mobiliza-
tion performance on GF is only partially determined by
clinical characteristics identiﬁable before initiation ofort according to their classiﬁcation as poor mobilizers (PM) or good mobilizers
deﬁned as PB-CD34þ < 10/mm3. Error bars represent median and interquartile
Table 3
Implications of Using the Best Fit Model for Risk Stratiﬁcation based on Clinical Variables and Assignment to Different Mobilization Strategies
Objective PS Cut-off* Sensitivityy Speciﬁcityy Implicationsy
Deﬁnition of Poor Mobilizer as PB-CD34þ < 20/mm3
To properly detect 80% of the PM prior to starting mobilization so an alternative
mobilization strategy can be used
26.7 80.1% 44.6% 19.9% of the PM (or 12.2% of the population) will not be allocated to alternative
mobilization strategy and will have mobilization failure or suboptimal collection.
55.4% of the GM (or 21.4% of the population) will be wrongfully predicted to be PM
and will receive unnecessary alternative mobilization strategy.
To properly detect 90% of the PM prior to starting mobilization so an alternative
mobilization strategy can be used
29.7 89.7% 34.8% 10.3% of the PM (or 6.3% of the population) will not be allocated to alternative
mobilization strategy and will have mobilization failure or suboptimal collection.
65.2% of the GM (or 25.2% of the population) will be wrongfully predicted to be PM
and will receive unnecessary alternative mobilization strategy.
To properly detect 80% of the GM so they can be spared the toxicity and cost of an
alternative mobilization strategy
19.8 47.3% 76.1% 52.7% of the PM (or 32.3% of the population) will not be allocated to alternative
mobilization strategy and will have mobilization failure or suboptimal
collection.23.9% of the GM (or 9.2% of the population) will be wrongfully predicted
to be PM and will receive unnecessary alternative mobilization strategy.
To properly detect 90% of the GM so they can be spared the toxicity and cost of an
alternative mobilization strategy
17.4 37.0% 86.9% 63% of the PM (or 38.6% of the population) will not be allocated to alternative
mobilization strategy and will have mobilization failure or suboptimal
collection.13.1% of the GM (or 5.1% of the population) will be wrongfully predicted
to be PM and will receive unnecessary alternative mobilization strategy
Deﬁnition of poor mobilizer as PB-CD34þ < 10/mm3
To properly detect 80% of the PM prior to starting mobilization so an alternative
mobilization strategy can be used
23.9 80% 52% 20% of the PM (or 5.5% of the population) will not be allocated to alternative
mobilization strategy and will have mobilization failure or suboptimal collection.
48% of the GM (or 34.9% of the population) will be wrongfully predicted to be PM
and will receive unnecessary alternative mobilization strategy.
To properly detect 90% of the PM prior to starting mobilization so an alternative
mobilization strategy can be used
27.6 89.2% 32.4% 10.8% of the PM (or 2.9% of the population) will not be allocated to alternative
mobilization strategy and will have mobilization failure or suboptimal collection.
67.6% of the GM (or 49.1% of the population) will be wrongfully predicted to be PM
and will receive unnecessary alternative mobilization strategy.
To properly detect 80% of the GM so they can be spared the toxicity and cost of an
alternative mobilization strategy
18.9 63.1% 74.6% 36.9% of the PM (or 10% of the population) will not be allocated to alternative
mobilization strategy and will have mobilization failure or suboptimal
collection.25.4% of the GM (or 18.5% of the population) will be wrongfully predicted
to be PM and will receive unnecessary alternative mobilization strategy.
To properly detect 90% of the GM so they can be spared the toxicity and cost of an
alternative mobilization strategy
15.6 43.1% 87.9% 56.9% of the PM (or 15.5% of the population) will not be allocated to alternative
mobilization strategy and will have mobilization failure or suboptimal
collection.12.1% of the GM (or 8.7% of the population) will be wrongfully predicted
to be PM and will receive unnecessary alternative mobilization strategy
PS indicates predictive score; PM, poor mobilizers; GM, good mobilizers.
* PS as derived from the training cohort.
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mobilizers before initiation of mobilization so they can be
assigned to another mobilization strategy (eg, planned
plerixafor or chemotherapy mobilization) would have
resulted in over treatment of 25.2%, although still having
poor mobilization in 6.3% of the patients (Table 3). It is
important to emphasize that even though we believe our
ﬁndings clearly indicate the limitations of using clinical
characteristics to predict mobilization failure, variations in
CD34þ enumeration likely also affected the results.
The above ﬁndings provide support to the strategy of “just
in time” use of plerixafor based on PB-CD34þ enumeration
over any strategy based on clinical characteristics. With “just
in time” approach, patients receive steady state mobilization
with growth factor only. After 4 or 5 days, patients reaching a
prespeciﬁed PB-CD34þ count proceed to collection whereas
patients with PB-CD34þ count inferior to the prespeciﬁed
threshold have plerixafor added to their mobilization
regimen and proceed to collection in the following day.
Strategies for “just in time” plerixafor as published by the
Mayo Clinic group [13], MUSC group [12], and others [28-30]
do not rely on prediction by clinical characteristics and
ensure that plerixafor is only utilized for patients who are
actual poor mobilizers and likely to have inadequate collec-
tion (approximately 40% to 60% of patients). This approach
keeps the rate of poor mobilization at < 5% and the rate of
mobilization failure close to 0%. The limitations of predictive
systems for poor mobilization and the advantage of “just in
time” approaches have been acknowledged in a recently
published consensus paper in autologous mobilization [31].
In summary, clinical characteristics identiﬁable before
initiating mobilization are inadequate predictors of poor
mobilization and should not be used to stratify multiple
myelomapatients fordifferentmobilization strategies. “Just-in-
time” plerixafor is an attractive alternative to risk stratiﬁcation.
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